Benralizumab
Benralizumab
Definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
Also known as Anti-CD125 Humanized Monoclonal Antibody, IgG1-kappa, BENRALIZUMAB, BIW-8405, Fasenra, KHK-4563, MEDI-563 — per NCIT
Also identified as
- ATC R03DX10 per RXNORM
- NCIT NCIT:C88594 per NCIT
- SCTID 763651005 per RXNORM
- SCTID 763652003 per RXNORM
- UNII 71492GE1FX per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Asthma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Respiratory system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.